By Ryan Davis ( March 13, 2019, 4:47 PM EDT) -- The Patent Trial and Appeal Board on Wednesday invalidated every claim of a Pfizer patent tied to next generation pneumonia vaccines, handing a win to rival Merck Sharp & Dohme Corp., which persuaded the board to ax a patent for a different pneumonia vaccine last year....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.